Clinical trial NCT03649750: Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
Official title: A Phase I, Open-label, Single-dose, Randomized, 2-way Cross-over Study Designed to Examine the Relative Bioavailability of Guaifenesin When a Mucinex Extended Release 600 mg Bi-layer Tablet is Taken Under Fasted Compared to Fed Conditions in Normal Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: Reckitt Benckiser LLC
Sponsor class: INDUSTRY
First posted: 2018-08-28
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg bi-layer tablet in normal healthy volunteers in fed and fasting conditions


Eligibility criteria: Inclusion Criteria:

1. Informed consent was obtained (i.e. be informed of the nature of the study and given written consent prior to any study procedure). Able to read, understand, and sign the informed consent, after the nature of the study had been explained.
2. Age: 18 to 55 years of age, inclusive.
3. Sex: male or female.
4. Status: Healthy subjects.
5. BMI: ≥18.0 and ≤28.0 kg/m2.
6. No clinically significant findings in vital signs measurements at screening.
7. No clinically significant abnormal laboratory values at screening.
8. No clinically significant findings from a 12-lead electrocardiogram (ECG) at screening.
9. Had no significant diseases or clinically relevant medical condition in the opinion of the Investigator
10. Males who participated in this study were willing to:

    * remain abstinent \[not engage in sexual intercourse\] from the start of drug administration until 90 days after the end of the study or
    * used (or their partner used, as applicable) two effective methods of birth control \[condom, diaphragm, cervical cap, vaginal sponge, spermicide, IUD, tubal ligation, vasectomy, or hormonal contraceptives\] from the start of drug administration until 90 days after the end of the study.

    Females who participated in this study were:
    * unable to have children (e.g., post-menopausal, hysterectomy);
    * willing to remain abstinent \[not engage in sexual intercourse\] from 21 days prior to drug administration until 30 days after the end of the study; or
    * willing to use two effective methods of birth control \[condom, diaphragm, cervical cap, vaginal sponge, spermicide, non-hormonal Intrauterine Device (IUD) (in place for 3 months), tubal ligation, partner has vasectomy, hormonal contraceptives for 3 months prior to drug administration\] from 30 days prior to drug administration until 30 days after the end of the study.
11. Had no clinically significant findings from a physical examination.

Exclusion Criteria:

1. Employee of Pharma Medica Research Inc. (PMRI) or Reckitt Benckiser.
2. Partner or first-degree relative of any Investigator at PMRI.
3. Known history or presence of any clinically significant medical condition.
4. Known or suspected carcinoma.
5. Presence of hepatic or renal dysfunction.
6. Presence of clinically significant gastrointestinal disease or history of malabsorption within the year preceding the study.
7. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.
8. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
9. History of drug or alcohol or medicinal product addiction requiring treatment within the two years preceding the study or excessive alcohol consumption (more than 10 units per week)

   Note: one unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of spirits.
10. Positive test result for serum Human Chorionic Gonadotropin (hCG) consistent with pregnancy (females only), HIV, Hepatitis B surface antigen or Hepatitis C antibody.
11. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and benzodiazepines) or urine cotinine.
12. Difficulty fasting or consuming standard meals.
13. Females who were lactating.
14. Did not tolerate venipuncture.
15. Use of tobacco or nicotine-containing products within 12 months prior to drug administration.
16. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
17. Donation or loss of whole blood (including clinical trials):

    * ≥50 ml and ≤499 ml within 30 days prior to drug administration
    * ≥500 ml within 56 days prior to drug administration
18. Females who had started taking hormonal contraceptives or had changed their method or brand of hormonal birth control within 3 months prior to drug administration.
19. Had a tattoo or body piercing within 30 days prior to drug administration.
20. Use of drugs of the monoamine oxidase inhibitor (MAOI) class within 30 days prior to drug administration.
21. Known history or presence of hypersensitivity, intolerance or idiosyncratic reaction to guaifenesin or any other drug substances with similar activity.
22. Previously enrolled in this study.
23. Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
24. Unable in the opinion of the Investigator to comply fully with the study requirements.

Primary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
measure: Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
Secondary outcomes:
measure: Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
measure: Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
measure: Terminal Elimination Rate Constant (Kel) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
measure: Terminal Elimination Half-life (T½) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
measure: Relative Bioavailability (RF) of Guaifenesin
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
measure: Number of Adverse Events(AEs) Experienced by Participants
timeFrame: Up to period 2 (8.3 days/200 hours)
Other outcomes:
Locations:
Study officials:
References: